The "fraudulent scheme" allegedly cost investors billions of dollars.
"We have a very ethical company and we're very confident in terms of the future."
Quebec's securities regulator says it hasn't launched a formal investigation into Valeant, which has its headquarters in Laval near Montreal, but is watching the situation "very seriously.''
The deal Thursday comes one day after regulators approved the pill. Valeant expects the Sprout pill, Addyi, to be available